

Anthony M. Casapao, Pharm.D., M.P.H.

University of Florida College of Pharmacy | 580 W. 8th Street Jacksonville, FL 32209
(904) 244-9129 | Casapao@cop.ufl.edu

Education

2016 – 2018	Master in Public Health concentration in Epidemiology and Biostatistics Harvard University School of Public Health – Boston, Massachusetts
2005 – 2009	Doctor of Pharmacy, <i>Cum Laude</i> Wingate University School of Pharmacy – Wingate, North Carolina
2003 – 2005	Bachelor of Science in Biomedical Science, <i>Magna Cum Laude</i> Midwestern University – Glendale, Arizona
2000 – 2003	Associate in Science College of Lake County – Grayslake, Illinois

Professional Experience and Post-Graduate Training

July 2022 – Present	<i>Clinical Associate Professor</i>
October 2017– June 2022	<i>Clinical Assistant Professor</i> Department of Pharmacotherapy and Translational Research University of Florida College of Pharmacy – Jacksonville, FL Department Interim Chair: Michelle Farland, Pharm.D., CDCES Divisional Chair: Kalen Manasco, Pharm.D., BCPPS, FCCP, FPPA
June 2018 – Present	<i>Infectious Diseases Pharmacotherapy Specialist</i> Department of Pharmacy University of Florida Health Jacksonville – Jacksonville, FL Director: Bernadette Belgado, Pharm.D. Manager: Stephanie McCormick, Pharm.D., AE-C
January 2018 – Present	<i>Health Care-Associated Infection Advisory Board Member</i> Division of Disease Control & Health Protection Florida Department of Health – Tallahassee, FL Director: Nychie Dotson, Ph.D., M.P.H., CIC, CPHQ, FAPIC
April 2019 – Present	<i>Staff Pharmacist and Continuing Education Coordinator</i> Medtown Pharmacy – Jacksonville, FL Supervisor: Chen Oeur, Pharm.D.
June 2021 – Present	<i>Board of Director Member</i> River Region Human Services – Jacksonville, FL Board Chair: Kay Fullwood CEO/President: Jacqueline Dowdy, Ph.D.
April 2014 – October 2017	<i>Assistant Professor</i> Department of Pharmacy Practice Husson University School of Pharmacy – Bangor, ME Chair: Ronald C. Reed, Pharm.D., FCCP, FAES
Sept 2014 – October 2017	<i>Clinical Infectious Diseases Pharmacotherapy Specialist</i> Department of Pharmacy Eastern Maine Medical Center – Bangor, Maine Director: James A. Cattin, BS, MS Manager: Jamie Cronin, Pharm.D., BCPS, BCPPS

Professional Experience and Post-Graduate Training, cont.

July 2015 – October 2017	<i>HAI Collaborating Partners Committee: Pharmacy Member</i> Maine Center for Disease Control and Prevention – Augusta, ME Coordinator: Rita Owsiak, MS, MT(ASCP)
Sept 2014 – October 2017	<i>Antimicrobial Stewardship Committee and Infection Prevention and Control Function Team Member</i> Eastern Maine Medical Center – Bangor, Maine Chair: Robert Pinsky, M.D.
August 2011– March 2014	<i>Infectious Diseases Outcomes Research Fellow</i> ACCP Peer Reviewed Fellowship Program Wayne State University EACPHS - Detroit, MI Directors: Michael J. Rybak, Pharm.D., MPH, FCCP, FIDSA Susan L. Davis, Pharm.D.
August 2011– March 2014	<i>Adjunct Instructor</i> Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences Director: Michael J. Rybak, Pharm.D., MPH, FCCP, FIDSA
July 2010 – July 2011	<i>Post Graduate Year-2 Infectious Diseases</i> ASHP-Accredited Residency Program University of Pittsburgh Medical Center – Pittsburgh, PA Residency Director: Brian A. Potoski, Pharm.D., BCPS AQ-ID
September 2010 – June 2011	<i>Adjunct Instructor</i> Teaching Certificate Program University of Pittsburgh School of Pharmacy – Pittsburgh, PA Program Director: Denise L. Howrie, Pharm.D.
June 2009 – July 2010	<i>Post Graduate Year-1 Pharmacy Practice</i> Residency Program (ASHP-Accredited) St. Vincent's Medical Center – Jacksonville, FL Residency Director: Michele Loudy, Pharm.D., BCPS
July 2009 – July 2010	<i>Adjunct Instructor</i> Teaching Certificate Program University of Florida College of Pharmacy – Jacksonville, FL Program Director: Lisa D. Inge, Pharm.D., BCPS, AAHIVE
Summer 2007	<i>Pharmacy Intern</i> Harris Teeter Store #129 – Indian Trail, North Carolina Pharmacy Manager: Kevin Pultorak, R.Ph.
2001 – 2003	<i>Pharmacy Technician</i> Highland Park Hospital – Highland Park, IL Pharmacy Director: Mike Sura, Pharm.D.
2000 – 2002	<i>Pharmacy Technician</i> Walgreen's Pharmacy – Libertyville, Illinois Pharmacy Manager: Lowell Sederstrom, R.Ph.

Clinical Teaching Experience

2017 – Present	<i>Preceptor, Academia Advanced Pharmacy Practice Experience</i> UF Health JAX/ UF COP; 2017-Present
2011 – Present	<i>Preceptor, PGY2 Infectious Diseases Pharmacy Residency</i> UF Health JAX, Jacksonville, Florida; 2020-Present Maine Medical Center, Portland, Maine; 2016-2018 Detroit Receiving Hospital, Detroit, Michigan; 2011-2013
2011 – Present	<i>Preceptor, PGY1 Pharmacy Practice Residency</i> UF Health JAX, Jacksonville, Florida; 2018-Present Baptist Health/Wolfson's Children, Jacksonville, Florida; 2019-Present Ascension St. Vincent's Riverside, Jacksonville, Florida; 2020-Present Eastern Maine Medical Center, Bangor, Maine; 2015-2016 UPMC – Presbyterian Hospital, Pittsburgh, Pennsylvania; 2011
2009 – 2017	<i>Preceptor, Infectious Disease Advanced Pharmacy Practice Experience</i> Eastern Maine Medical Center / HUSOP (RX611); 2014-2017 Detroit Receiving Hospital / EACPHS (PPR7530); 2011-2014 UPMC Presbyterian Hospital / UPSP (PHARM5402); 2010 St. Vincent's Medical Center / FAMU CPPS; 2009
2015 – 2017	<i>Preceptor, Hospital Introductory Pharmacy Practice Experience</i> Eastern Maine Medical Center / Husson University (RX550); 2015-2017
2015 – 2016	<i>Preceptor, Research Advanced Pharmacy Practice Experience</i> Eastern Maine Medical Center / Husson University (RX617); 2015-2016
2009 – 2010	<i>Preceptor, Drug Information Advanced Pharmacy Practice Experience</i> St. Vincent's Medical Center / UF COP; 2009

Didactic Teaching Experience

University of Florida College of Pharmacy, Jacksonville, Florida

2021 – Present	<i>Introduction to Infectious Disease and Hematology/Oncology (PHA5782C)</i> – 6 credit hours, distance education, team-based learning Course Director, Instructor, Lecturer, and Facilitator P2 PharmD candidates
2018 – Present	<i>Advanced Topics in Infectious Disease (PHA5605)</i> – 2 credit hours, distance education, taught to all three campuses Course Director, Instructor, Lecturer, and Facilitator P3 PharmD candidates
2018 – Present	<i>Advanced Pharmacy Practice Experiential Readiness (PHA5759)</i> – 1 credit hour, on-site education, experiential learning Campus Facilitator P3 PharmD candidates
2018 – Present	Pharmacotherapy and Translational Research Elective (PHA5907) – 2 credit hours, on-site education, active learning Course Director, Instructor, Lecturer, and Facilitator P2 and P3 PharmD candidates

Didactic Teaching Experience, cont.**University of Florida College of Pharmacy, Jacksonville, Florida**

2019 – 2022	<i>Professional Practice Skills Lab III (PHA5163L)</i> – 1 credit hour on-site education, active learning, team-based and collaborative learning Campus Facilitator P2 PharmD candidates
2018 – 2022	<i>Personal and Professional Development (PHA5702C)</i> – 1 credit hour distance education, collaborative learning Campus Facilitator P3 PharmD candidates
2018 – 2020	<i>Principles of Medical Microbiology, Immunology & Virology (PHA5755)</i> – 2 credit hours, distance education, team-based learning Course Director, Instructor, Lecturer, and Facilitator P2 PharmD candidates
2020	<i>Foundations of Clinical Practice Course (PHA59560)</i> – 6 credit hours online distance education, experiential learning Instructor and Facilitator P4 PharmD candidates
2018 – 2020	<i>Professional Practice Skills Lab VI (PHA5166L)</i> – 1 credit hour on-site education, active learning, team-based and collaborative learning Campus Facilitator P3 PharmD candidates
2017 – 2019	<i>Professional Practice Skills Lab V (PHA5165L)</i> – 1 credit hour on-site education, active learning, team-based and collaborative learning Campus Facilitator P3 PharmD candidates
2017 – 2019	<i>Professional Practice Lab I (PHA5161L)</i> – 1 credit hour on-site education, active learning, team-based and collaborative learning Campus Facilitator P1 PharmD candidates
2019	Pharmacy Residency Application Preparation Workshop Series. distance education, active learning Instructor and Lecturer P2 and P3 PharmD candidates
2019	<i>Professional Practice Skills Lab II (PHA5162L)</i> – 1 credit hour on-site education, active learning, team-based and collaborative learning Campus Facilitator P1 PharmD candidates
2017	<i>History of Pharmacy (PHA5020)</i> – 2 credit hours distance education, collaborative learning Campus Facilitator P3 PharmD Candidates

Didactic Teaching Experience, cont.

University of Florida College of Pharmacy, Jacksonville, Florida

2009 Pharmaceuticals Skills Laboratory (PHA 5108L) – 1 credit hour
on-site education, active learning, team-based and collaborative learning
Campus Facilitator
P3 PharmD candidates

Husson University School of Pharmacy, Bangor, Maine

2016 – 2017 *Infectious Diseases Pharmacotherapy Elective (RX 569)* – 2 credit hours
active and collaborative learning
Course Director, Lecturer, and Facilitator
P3 PharmD candidates

2015 – 2017 *Infectious Diseases Research (RX 490)* – 2 credit hours
active learning and experiential learning
Course Director and Lecturer
P1, P2, and P3 PharmD candidates

2015 – 2017 *Pharmacy Capstone (RX542)* – 2 credit hours
active learning and collaborative learning
Course Director, Lecturer, and Facilitator
P3 PharmD candidates

2015 – 2017 *Pharmacotherapeutics I (RX474)* – 3 credit hours
active learning and collaborative learning
Lecturer - Introduction and Review of Antimicrobial Agents
Lecturer - Pharmacokinetics of Vancomycin and Aminoglycosides
P2 PharmD candidates

2015 – 2017 *Medical Microbiology (RX342)* – 3 credit hours
active learning
Lecturer - Pharmacy applications of microbiology
P1 PharmD candidates

2015 – 2017 *Pharmacotherapeutics III (RX522)* – 4 credit hours (2017)
Drug Action VI (RX522) – 4 credit hours (2015-2016)
active learning
Lecturer - Sexual Transmitted Infections
Lecturer - Urinary Tract Infections
Lecturer - Meningitis
P3 PharmD candidates

2015 – 2017 *Applied Pharmacotherapeutics II Recitation (RX592)* – 2 credit hours
active learning and collaborative learning
Lecturer/Facilitator - Sexual Transmitted Infections and
Lecturer/Facilitator - Meningitis
P3 PharmD candidates

2015 – 2016 *Principals of Pharmacokinetics (RX433)* – 3 credit hours
active learning
Lecturer - Aminoglycosides pharmacokinetics
P2 PharmD candidates

Didactic Teaching Experience, cont.**Husson University School of Pharmacy, Bangor, Maine**

2014 – 2016	<i>Applied Pharmacotherapeutics I Recitation (RX591)</i> – 2 credit hours active learning and collaborative learning Lecturer/Facilitator Introduction of Antimicrobial Agents (2014-2015) Lecturer/Facilitator Pharmacokinetics of Vancomycin (2014-2015) Lecturer/Facilitator Pharmacokinetics of Aminoglycosides (2014-2015) Lecturer/Facilitator Pneumonia (2014-2016) Lecturer/Facilitator Infective Endocarditis (2014-2016)
2014 – 2016	<i>Applied Pharmacotherapeutics I Recitation (RX591)</i> – 2 credit hours active learning and collaborative learning Lecturer/Facilitator Urinary Tract Infections (2014-2015) P3 PharmD candidates
2014 – 2016	<i>Pharmacotherapeutics II (RX521)</i> – 4 credit hours (2016) <i>Drug Action V (RX521)</i> - 4 credit hours (2014-2015) active learning Lecturer - Lower respiratory tract Infections (2016) Lecturer - Introduction and Review of Antimicrobial Agents (2014-2015) Lecturer - PK of Vancomycin and Aminoglycosides (2014-2016) Lecturer – Pneumonia (2014-2015) Lecturer - Infective Endocarditis (2014-2016) Lecturer - Urinary Tract Infections (2014-2015) P3 PharmD candidates
2015 – 2016	<i>NAPLEX Live Review Session</i> Lecturer - Infectious Diseases Pharmacotherapy Review Recent P4 PharmD graduates
2016	<i>Critical Care Pharmacotherapy (RX582)</i> – 2 credit hours Lecturer - Antimicrobial Therapy Considerations in Critically Ill P3 PharmD candidates
2015 – 2016	<i>Drug-Drug Interactions (RX564)</i> – 2 credit hours Lecturer - Gastrointestinal Drug-Drug Interactions P2 and P3 PharmD candidates
2015 – 2016	<i>Cognitive, Communication, and Case-Based Critical Thinking IV (RX432)</i> – 3 credit hours active learning and collaborative learning Lecturer/Facilitator P2 PharmD candidates
2014 – 2015	<i>Pharmacy Seminar (RX551)</i> – 2 credit hours Lecturer - Drug Literature Evaluation P3 PharmD candidates
2014	<i>Geriatric Pharmacotherapy Elective (RX490.001)</i> - 2 credit hours Lecturer - Respiratory, Renal, and Urological Disorders in Elderly P3 PharmD candidates

Didactic Teaching Experience, cont.

**Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences,
Detroit, Michigan**

- 2012-2013 *Principles of Pharmacotherapy 3 (PHA 4210)* – 4 credit hours
Respiratory and Infectious Diseases Pharmacotherapy
active learning
Lecturer - Skin and Soft Tissue Infections and Surgical Prophylaxis.
P2 PharmD candidates
- 2012 *Pharmacotherapy Problem Solving (PHA 5270)* – 4 credit hours
active learning and collaborative learning
Facilitator
P3 PharmD candidates
- 2012-2013 *Directed Study in Pharmacy Practice (PPR 7990)* – 3 credit hours
active learning and collaborative learning
Facilitator
P2 PharmD candidates

University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania

- 2011 *Advanced Pharmaceutical Care 2 (PHARM 5321)* – 1 credit hour
active learning and collaborative learning
Facilitator
P3 PharmD candidates
- 2011 *Pharmacotherapy of Infectious Diseases 2 (PHARM 5215)* – 4 credit hrs
Lecturer - Introduction to Mycoses
Lecturer - Candidiasis
P2 PharmD candidates
- 2011 *Advanced Pharmaceutical Care 1 (PHARM 5225)* – 1 credit hour
Facilitator
P2 PharmD candidates
- 2011 *Profession of Pharmacy 2 (PHARM 5111)* – 2 credit hours
Facilitator
P1 PharmD candidates
- 2011 *Pharmacotherapy of Gastroenterology/Nutrition (PHARM 5223)* – 2
credit hours. Facilitator
P2 PharmD candidates
- 2010 *Pharmacotherapy of Cardiovascular Diseases (PHARM 5216)* – 4 credit
hours. Facilitator
P2 PharmD candidates
- 2010 *Profession of Pharmacy 1 (PHARM 5110)* – 2 credit hours
Facilitator
P1 PharmD candidates

Publications (Peer-Reviewed)

- 28) Dupree LH, **Casapao AM**. Research and scholarly methods: Writing abstracts. Journal of the American College of Clinical Pharmacy 2023 May 20; doi: 10.1002/jac5.1822
- 27) Cole JCC, Jankowski CA, Verdecia JL, Isache CL, Ravi MS, McCarter YS, **Casapao AM**. The time for action is now: the impact of timing of infectious disease consultation for *Staphylococcus aureus* bacteremia. Clin Infect Dis 2023 Jun 8;76(11):2007-2009.
- 26) Kunz-Coyne A, Alshaer M, **Casapao AM**, Venugopalan V, Isache C, Ferreira J, Jankowski CA. Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with *Pseudomonas aeruginosa* Pneumonia or Bloodstream Infection. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0064622.
- 25) Kunz-Coyne A, **Casapao AM**, Jankowski CA. Influence of antimicrobial stewardship and molecular rapid diagnostic test on antimicrobial prescribing for extended-spectrum beta-lactamase and carbapenemase-producing bacteria in bloodstream infections. Microbiol Spectr. 2021 Oct 31;9(2):e0046421
- 24) Piccuiro, SR, **Casapao AM**, Claudio AM, Isache C, Jankowski CA. Comparison of acute kidney injury in patients prescribed vancomycin in combination with piperacillin-tazobactam or cefepime for diabetic foot infections. J Investig Med. 2021 Jan 25;jim-2020-001594.
- 23) Jankowski CA, **Casapao AM**, Siller S, Isache C, Vahdat K, Claudio AM, Brown M, Feldhammer M. Capillary blood sampling is reliable methods for therapeutic drug monitoring of vancomycin. Am J Clin Pathol. 2021 Feb 11;155(3):412-417.
- 22) Shoulders B, **Casapao AM**, Venugopalan V. An Update on Existing and Emerging Data for Meropenem-Vaborbactam. Clin Ther. 2020 Apr;43(4):692-702.
- 21) Egelund EF, **Casapao AM**. Pet Nemo's Pills – The Last Loophole in Antimicrobial Stewardship? Clin Infect Dis. 2019 Jan 1;70(1):177-179.
- 20) Ortwine JK, Zasowski EJ, Pogue JM, Hanni C, Giuliano C, **Casapao AM**, Mynatt R, Rybak MJ. Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated. Infect Dis Ther. 2019 Dec;8(4):627-640.
- 19) Allen JM, Bakare L, **Casapao AM**, Klinker K, Childs-Kean LM, Pomputius AF. Cefazolin versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible *Staphylococcus aureus* Infection: A Meta-Analysis with Trial Sequential Analysis. Infect Dis Ther. 2019 Dec;8(4):671-686.
- 18) Claeys KC, Zasowski EJ, Trinh TD, **Casapao AM**, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ. Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline fosamil versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant *Staphylococcus aureus*. Infect Dis Ther. 2019 June;8(2):199-208.
- 17) Dilworth TJ, **Casapao AM**, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC. Adjuvant Beta-lactam Therapy Combined with Vancomycin for Methicillin-Resistant *Staphylococcus aureus* Bacteremia: Does Beta-lactam class matter? Antimicrob Agents Chemother. 2019 Mar;63(3):e02211-18.

Publications (Peer-Reviewed), cont.

- 16) Trinh TD, Zasowski EJ, Claeys KC, **Casapao AM**, Compton M, Lagnf A, Kidambi SD, Levine DP, Rybak MJ. Role of Vancomycin Minimum Inhibitory Concentration by Modified Population Analysis Profile Method in High Inoculum Methicillin-Resistant *Staphylococcus aureus* Infections. *Infect Dis Ther* 2018 Mar;7(1):161-9.
- 15) Jacobs DM, Dilworth TJ, Beyda NE, **Casapao AM**, Bowers DR. Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: A Multi-institutional Study. *Antimicrob Agents Chemother*. 2017 Dec 21;62(1), pii: e01464-17.
- 14) **Casapao AM**, Jacobs DM, Bowers DR, Beyda NE, Dilworth TJ. Early Administration of Adjuvant β -lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection: A Retrospective, Multicenter Analysis. *Pharmacotherapy*. 2017 Nov;37(11):1347-56.
- 13) Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ. A Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2017 Jan;61(2). pii:e0215-16.
- 12) Bosso JA, **Casapao AM**, Edwards J, Klinker K, McCoy C, Nicolau DP, Perez KK, Marcarelli A, Dua D. Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. *Hosp Pract (1995)*. 2016 Oct;44(4):183-189.
- 11) Claeys KC, Zasowski EJ, **Casapao AM**, Lagnf AM, Nagel JL, Nguyen CT, Hallesy J, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2016 Sep 23;60(10):5841-8.
- 10) Lagnf AM, **Casapao AM**, Claeys KC, Rybak MJ. Comparison of Clinical Outcomes and Risk Factors in Polymicrobial versus Monomicrobial Enterococcal Bloodstream Infections. *Am J Infect Control* 2016; Aug;44(8):917-21.
- 9) **Casapao AM**, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. Association Between Vancomycin Day 1 Exposure Profile and Outcomes Among Patients with Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. *Antimicrob Agents Chemother*. 2015 Jun;59(6): 2978-85.
- 8) Claeys KC, Smith JR, **Casapao AM**, Mynatt RP, Avery L, Shroff A, Yamamura D, Davis SL, Rybak MJ. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant *Staphylococcus aureus* infections. *Antimicrob Agents Chemother*. 2015 Apr;59(4):1969-76.
- 7) Sakoulas G, Moise PA, **Casapao AM**, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia using Daptomycin Plus Ceftaroline. *Clin Ther*. 2014 Oct 1;36(10):1317-33.

Publications (Peer-Reviewed), cont.

- 6) **Casapao AM**, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, Levine DP, Rybak MJ. Evaluation of Vancomycin Population Analysis Profile Susceptibility as a Predictor of Patient Outcomes with Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. *Antimicrob Agents Chemother*. 2014 Aug;58(8):4636-41.
- 5) **Casapao AM**, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. A Large Multicenter Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy for Severe Infections. *Antimicrob Agents Chemother*. 2014 May;58(5):2541-6.
- 4) Kullar R, **Casapao AM**, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. A Multicentre Evaluation of the Effectiveness and Safety of High-Dose Daptomycin for the Treatment of Infective Endocarditis. *J Antimicrob Chemother*. 2013 Dec;68(12):2921-6.
- 3) **Casapao AM**, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections. *Antimicrob Agents Chemother*. 2013 Sep;57(9):4190-6.
- 2) **Casapao AM**, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, LaPlante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate *Staphylococcus aureus* (hVISA) bloodstream infection. *Antimicrob Agents Chemother*. 2013 Sep;57(9):4252-9.
- 1) **Casapao AM**, Steed ME, Levine DP, Rybak MJ. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. *Expert Opin Pharmacother*. 2012 Jun;13(8):1177-86.

Book Chapters

- 4) Kunz Coyne AJ. **Casapao AM**. Egelund EF. The Pharmacokinetic and Pharmacodynamic Properties of Antitubercular Medication. Update on TUBERCULOSIS: Integrated Studies for a Complex Disease. Springer; 2023 April; 257-275. doi: 10.1007/978-3-031-15955-8_14.
- 3) Baek Y. Egelund EF. **Casapao AM**. Chapter 28: Principles of Antimicrobial Therapy. Lippincott Illustrated Reviews: Pharmacology, Eighth Edition. Lippincott Williams & Wilkins; 2022.
- 2) **Casapao AM**. Community-Acquired Pneumonia. *PharmacotherapyFirst: A Multimedia Learning Resource*. American Pharmacists Association; 2020. Available at: https://pharmacylibrary.com/doi/full/10.21019/pharmacotherapyfirst.cap_overview (peer-reviewed)
- 1) **Casapao AM**. Interactive Case: Combination Antibiotics for *Staphylococcus aureus*. Infectious Diseases Self-Assessment Program 2020 Book 2 Resistant Gram-Positive Infections. American College of Clinical Pharmacy and American Society of Health-System Pharmacists; 2020;171-177. (peer-reviewed)

Abstracts

International

- 2020 Carr A, Minor S, El Ghali, Kaur P, **Casapao AM**. Early real-world evidence in the use of eravacycline therapy for the management of draconian infections. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #4006.
- 2020 Wungwattana M, Mangino M, Ben G, Stogsdill P, **Casapao AM**. Does early de-escalation to anti-staphylococcal beta-lactams impact the duration of bacteremia in patients with methicillin-susceptible *Staphylococcus aureus* endocarditis? 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #3049. (cancelled due to COVID-19). ***Presented as a research platform presentation.***
- 2020 Venugopalan V, Hernandez S, DeSear K, Peloquin C, Cherabuddi K, **Casapao AM**. Use of therapeutic drug monitoring to optimise cephazolin dosing in the treatment of methicillin-susceptible *Staphylococcus aureus* bacteremia. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #2657.
- 2020 Nilles L, Pirasteh A, Sothoron C, Tucker C, **Casapao AM**. Effectiveness of Using Oral Vancomycin as Prophylaxis for *Clostridium difficile* Infections in High-Risk Patients. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 2020; Abstract #3676.
- 2017 **Casapao AM**, Mahlen SD. Evaluation of Ceftaroline and Telavancin Susceptibilities against Enterococcal Bloodstream Isolates. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #4328.
- 2017 **Casapao AM**, Wungwattana M. The landscape of *Pseudomonas aeruginosa* clinical isolates in rural Northeastern United States and the Potential Impact on Hospital Mortality. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #7097.
- 2017 **Casapao AM**, Mahlen SD. Ceftazidime-avibactam and ceftolozane-tazobactam activity against *Escherichia coli* producing CTX-M beta-lactamases. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #5215.
- 2016 Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Sabagha N, Hallesy J, Rybak MJ. Relationship between Duration of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection and Mortality. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 2016; Abstract #6407.
- 2016 Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Sabagha N, Rybak MJ. Ceftaroline Fosamil for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 2016; Abstract #6408.

Abstracts, continued

International

- 2015 Zasowski EJ, Lagnf AM, **Casapao AM**, Rybak MJ. Impact of Delayed Antibiotic Therapy on Outcomes of Patients with Hospital-Onset Enterococcal Bacteremia (EB): A Retrospective Cohort Study. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2015; Abstract #eP163.
- 2014 **Casapao AM**, Davis SL, Barr VO, Goff DA, Kaye KS, Pogue JM, Rybak MJ. Retrospective Multi-Centre Experience of the Effectiveness and Safety with Ceftaroline Fosamil Therapy in Patients with Acute Bacterial Skin and Skin Structure Infections. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP422.
- 2014 **Casapao AM**, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. The Effectiveness and Safety with Ceftaroline Fosamil Therapy for Lower Respiratory Tract Infections in a Retrospective Multi-Centre Study. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP425.
- 2014 Claeys KC, **Casapao AM**, Pogue JM, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado Jr. G , Giuliano CA, Takla R Johnson LB, Davis SL, Rybak MJ. Rapid Diagnostic Testing with GeneXpert Improves Enrollment in a Randomised Clinical Trial for Detection of Methicillin-Resistant *Staphylococcus aureus* in Acute Bacterial Skin and Skin Structure Infections. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #P1471.
- 2013 **Casapao AM**, Davis SL, Kullar R, Patel S, Levine DP, Rybak MJ. An Alternative Susceptibility Method as Predictor of Clinical Response to Vancomycin (VAN) with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 12th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, International Society of Cardiovascular Infectious Disease s (ISCVID), Dubronik, Croatia, May 2013; Abstract # P41.
- 2013 **Casapao AM**, Barber KE, Wong CK, Barr V, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Clinical experience with ceftaroline fosamil (CPT) for bloodstream infections (BSI). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 2013; Abstract # 3369.
- 2013 **Casapao AM**, Patel S, Kullar R, Davis SL, Levine DP, Rybak MJ. Evaluation of vancomycin exposure on outcomes in a cohort of patients with methicillin-resistant *Staphylococcus aureus* (MRSA) infective endocarditis (IE). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 2013; Abstract # 2655. ***Presented as a research platform presentation.***

National

- 2022 Cole JC, Jankowski CA, Verdecia JL, Isache CL, Ravi MS, McCarter YS, **Casapao AM**. The time for action is now: The impact of timing of infectious disease consultation for *Staphylococcus aureus* bacteremia. 11th Annual IDweek Meeting, October 2022.

Abstracts, continued

National

- 2021 Kunz Coyne, AJ, **Casapao AM**, Al-Shaer MH, Isache C, Ferreira J, Jankowski CA. Efficacy and safety of beta-lactam antibiotics with and without therapeutic drug monitoring in patients with *Pseudomonas aeruginosa* pneumonia or bacteremia. 10th Annual IDweek Meeting, October 2021.
- 2020 Kunz Coyne AJ, **Casapao AM**, Isache C, Morales J, McCarter YS, Jankowski CA. Influence of antimicrobial stewardship and molecular rapid diagnostic test on antimicrobial prescribing for extended-spectrum beta-lactamase and carbapenemase-producing bacteria in bloodstream infections. 9th Annual IDweek Meeting, October 2020.
- 2020 Carr A, Minor S, El Ghali, Kaur P, **Casapao AM**. Early real-world evidence in the use of eravacycline therapy for the management of draconian infections. 9th Annual IDweek Meeting, October 2020.
- 2018 Dilworth TJ, **Casapao AM**, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC. Adjuvant Beta-lactam Therapy Combined with Vancomycin for Methicillin-Resistant *Staphylococcus aureus* Bacteremia: Does Beta-lactam class matter? 56th Annual Infectious Diseases Society of America Conference combined with 7th Annual IDweek Meeting, San Francisco, California, October 2018; Abstract #70673.
- 2018 Lee S. Jones SJ. **Casapao AM**. Empiric antimicrobial therapy and readmission to the emergency department in patients with urinary tract infections. 52nd Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Orlando, Florida, December 2017; Abstract #12-042. 56th Annual Infectious Diseases Society of America Conference combined with 7th Annual IDweek Meeting, San Francisco, California, October 2018; Abstract #73171.
- 2018 Thomas LO, Jones SJ, **Casapao AM**. Adherence to empiric treatment recommended by IDSA/PIDS pediatric community-acquired pneumonia (CAP) guidelines according to immunization status. 52nd Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Orlando, Florida, December 2017; Abstract #12-043. 56th Annual Infectious Diseases Society of America Conference combined with 7th Annual IDweek Meeting, San Francisco, California, October 2018; Abstract #72739.
- 2017 Rusby MLM, **Casapao AM**. Decision analysis and cost-effectiveness analysis of antibiotic prescribed for COPD patients with acute exacerbation at a primary care setting. 52nd Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Orlando, Florida, December 2017; Abstract #12-056.
- 2017 Jacobs DM, Dilworth TJ, Beyda ND, **Casapao AM**, Mashtare T, Bowers DR. Characterization of Candiduria Treatment: A Multi-Institutional Study. 117th American Society for Microbiology Microbe Conference, New Orleans, Louisiana, June 2017; Abstract #4041.
- 2016 Ravin K, **Casapao AM**. Effect of hospital stay duration in patients treated with aztreonam vs cefepime for gram negative empiric therapy: interim analysis. 51st Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 2016; Abstract #2-160.

Abstracts, continued

National

- 2016 Laliberte NF, Ki MJ, **Casapao AM**, Wungwattana M. Susceptibility of *Pseudomonas aeruginosa* bloodstream isolates in Maine and the implications for selection of empiric antibiotic regimens. 51st Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 2016; Abstract #2-179.
- 2016 Rusby MLM, **Casapao AM**. Implementation of a pediatric antimicrobial stewardship in a primary care setting. 51st Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 2016; Abstract #12-010.
- 2016 Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Rybak MJ. Predictors of Heterogenous Vancomycin-Intermediate *Staphylococcus aureus* among Patients with Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. 116th American Society for Microbiology Microbe Conference in conjunction with 56th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, June 2016; Abstract #436-4.
- 2016 Ki MJ, Wilson C, Wungwattana M, Malen SD, **Casapao AM**. Evaluation of Ceftolozane/Tazobactam Susceptibilities of *Pseudomonas aeruginosa* Blood Isolates at Two Major Tertiary Referral Medical Centers. 116th American Society for Microbiology Microbe Conference in conjunction with 56th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, June 16-20, 2016; Abstract #259.
- 2016 Wungwattana M, Malen SD, **Casapao AM**. Susceptibility of *Pseudomonas aeruginosa* Bloodstream Isolates to Ceftazidime-Avibactam in Northeastern United States. 116th American Society for Microbiology Microbe Conference in conjunction with 56th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, June 2016; Abstract #257.
- 2016 Rusby M, Thorton L, Ng YT, **Casapao AM**. Pharmacoepidemiology of pediatric patients with bronchiolitis. 50th Annual American Society of Hospital-System Pharmacists. *Encore presentations*: Pediatric Pharmacy Advocacy Group 25th Annual Conference, Atlanta, Georgia, May 2016; Abstract # 88.
- 2015 Leichtweis CL, **Casapao AM**, Boudreau M, Mahlen S. Evaluation of empiric antimicrobial therapy and resistance of catheter-associated urinary tract infections versus non-catheter associated urinary tract infections in a level II trauma center. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015.
- 2015 Lee J, **Casapao AM**, Marston M. Evaluation of empiric and definitive therapy for febrile neutropenia. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-119.
- 2015 Wilson C, Graffam J, **Casapao AM**, Mahlen S. Evaluation of ceftolozane/tazobactam susceptibilities in *Pseudomonas aeruginosa* bloodstream isolates at level II trauma tertiary hospital. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-129.

Abstracts, continued

National

- 2015 Rusby M, Thorton L, Ng YT, **Casapao AM**. Pharmacoepidemiology of pediatric patients with bronchiolitis. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-125.
- 2015 Tran K, **Casapao AM**. Pharmacoepidemiology of Enterobacter infections at a level two tertiary medical center. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-126.
- 2015 **Casapao AM**, Jacobs DM, Bowers DR, Beyda NE, Dilworth TJ. Early Beta-Lactam Therapy Combined with Standard Therapy for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections compared to Standard Alone: A Multicenter, Retrospective, Propensity-Matched Analysis. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #B-071.
- 2015 Rusby M, Wilson C, **Casapao AM**. Impact of Mortality and Source of Infection in Intermediate Risk Patients with *Staphylococcus aureus* Bacteremia. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #K815.
- 2015 Wilson C, Rusby M, **Casapao AM**. Epidemiological Study of Obese Patients with *Staphylococcus aureus* Bacteremia at Eastern Maine Medical Center. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #K814.
- 2015 Zasowski EJ, Claeys KC, **Casapao AM**, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Pneumonia. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #B-081.
- 2015 Zasowski EJ, Claeys KC, **Casapao AM**, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil for the treatment of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #B-079.
- 2014 Trafton M, Boudreau M, Seavey W, **Casapao AM**. A Quasi-Experimental Study to Evaluate Drug Administration Complication in the Use of Extended Infusion Piperacillin/Tazobactam. 49th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Anaheim, California, December 2014; Abstract #10-187.
- 2014 **Casapao AM**, Lagnf AM, Rybak MJ. Temporal Characterization of Patients with Enterococcal Bloodstream Infection. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K1665.

Abstracts, continued

National

- 2014 Claey's KC, **Casapao AM**, Davis SL, Rybak MJ. Burden of Illness with Acute Bacterial Skin and Skin Structure Infections Evaluated in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K1702.
- 2014 Nagel JL, Pogue J, Claey's KC, **Casapao AM**, Finks J, Rybak MJ. Utilization of the Centers for Disease Control and Prevention National Healthcare Safety Network Antimicrobial Use and Resistance Module to Compare Multicenter Antimicrobial Use. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K332.
- 2014 Claey's KC, Nagel JL, **Casapao AM**, Pogue JM, Finks J, Davis SL, Rybak MJ. Implementing the National Healthcare Safety Network's Antimicrobial Use Option to Aid in Determination of Resistance Among Key Nosocomial Pathogens. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K327.
- 2013 Ni D, Rising K, **Casapao AM**, Barber KE, Mynatt RP, Rybak MJ. Vancomycin Consensus Guidelines Application and Serum Concentration Target Attainment. 48th ASHP Midyear Clinical Meeting Orlando, FL, December 2013; Abstract #1-316.
- 2013 **Casapao AM**, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. Multicenter Experience of the Effectiveness and Safety with Ceftaroline Fosamil (CPT) Therapy. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013; Abstract # K-192.
- 2013 McRoberts JP, **Casapao AM**, Lephart PR, Rybak MJ. Evaluation of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bloodstream Infections (BSI) Minimum Inhibitory Concentrations (MICs) to Vancomycin (VA) and Daptomycin (DAP) at an Urban Detroit Medical Institution. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013; Abstract # C2-080.
- 2013 **Casapao AM**, Davis SL, Levine DP, Rybak MJ. Characterization of Patients with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013; Abstract # K-1285.
- 2012 **Casapao AM**, Patel S, Kullar R, Davis SL, Rybak MJ. Evaluation of Population Analysis Profile Susceptibility (PAP) as a Predictor of Patient Outcomes with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-946.
- 2012 **Casapao AM**, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-Dose Daptomycin for Treatment of Enterococcal Infections: Multicenter, Retrospective Study. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-275.

Abstracts, continued

National

- 2012 Barber KE, **Casapao AM**, Pogue JM, Kaye KS, Rybak MJ. Outcomes Associated with Vancomycin Intermediate *Staphylococcus aureus* (VISA) Bloodstream Infections (BSI). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-906.
- 2012 **Casapao AM**, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-909.
- 2012 Martin ET, **Casapao AM**, McRoberts J, Archer C, Kaye KS, Rybak MJ. Low prevalence of Inc18-like *vanA* plasmid among prospectively-collected vancomycin-resistant *Enterococcus* isolates from Detroit Medical Center. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #C2-1985.
- 2012 **Casapao AM**, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-1123. *Presented as a research platform presentation.*
- 2011 Kasha MZ, Barber KE, **Casapao AM**, Mynatt RP, Rybak MJ. Vancomycin Consensus Guidelines Application and Serum Concentration Target Attainment: A Quality Assessment Evaluation. 46th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 2011; Abstract #4-157.
- 2011 **Casapao AM**, Potoski BA, Doi Y, Pasculle AW. *In vitro* susceptibilities of Fosfomycin against Enterobacteriaceae producing KPC-type Beta-lactamases. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, September 17-20, 2011; Abstract #E-725.
- 2010 Armahizer MJ, **Casapao AM**, Potoski BA. Persistent Bacteremia in a patient due to Vancomycin-Intermediate *Staphylococcus aureus* (VISA). 45th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2010; Abstract #6-150.
- 2009 **Casapao AM**, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 44th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2009; Abstract #7-125.

Regional

- 2023 Altamura E, Carrion Dominguez DA, **Casapao AM**, Egelund EF. Systematic Review of Medical Grade Honey versus Non-Medical Honey in Pet Wounds. 133rd Annual Florida Pharmacy Association, Marco Island, FL, July 2023.

Abstracts, continued

Regional

- 2022 Cole JC, Jankowski CA, Verdecia JL, Isache CL, , Ravi MS, McCarter YS, **Casapao AM**. The time for action is now: The impact of timing of infectious disease consultation for *Staphylococcus aureus* bacteremia. 11th Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, May 2022.
- 2022 Wasielewski AS, Jankowski CA, Kunz Coyne AJ, Isache CL, , Ravi MS, **Casapao AM**. Impact of Obesity on Clinical Outcomes of Methicillin-susceptible *Staphylococcus aureus* Bloodstream Infections. 11th Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, May 2022.
- 2022 Chang E, **Casapao AM**, Ravi MS, Isache CL, McCarter YS, Jankowski CA. Candidemia: A decade under antimicrobial stewardship at an academic medical center. 11th Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, May 2022.
- 2021 Kunz Coyne AJ, **Casapao AM**, Al-Shaer MH, Isache C, Ferreira J, Jankowski CA. Efficacy and safety of beta-lactam antibiotics with and without therapeutic drug monitoring in patients with *Pseudomonas aeruginosa* pneumonia or bacteremia. 10th Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, May 2021.
- 2020 Kunz Coyne AJ, **Casapao AM**, Isache C, Morales J, McCarter YS, Jankowski CA. Influence of antimicrobial stewardship and molecular rapid diagnostic test on antimicrobial prescribing for extended-spectrum beta-lactamase and carbapenemase-producing bacteria in bloodstream infections. 9th Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, May 2020.
- 2019 Nilles L, Pirasteh A, Sothoron C, Tucker C, **Casapao AM**. Effectiveness of Using Oral Vancomycin as Prophylaxis for *Clostridium difficile* Infections in High-Risk Patients. 8th Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, Tampa, Florida, May 2019.
- 2019 Cawoski HC, Johnson B, Stamper B, **Casapao AM**, Jankowski CA. A retrospective study comparing the clinical and economic outcomes of injection drug users versus non-injection drug users with endocarditis at a tertiary care center. 8th Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, Tampa, Florida, May 2019.
- 2018 Lee S. Jones SJ. **Casapao AM**. Empiric antimicrobial therapy and readmission to the emergency department in patients with urinary tract infections. 38th Annual Eastern States Conference, Hersey, Pennsylvania, May 2018.
- 2018 Thomas LO, Jones SJ, **Casapao AM**. Adherence to empiric treatment recommended by IDSA/PIDS pediatric community-acquired pneumonia (CAP) guidelines according to immunization status. 38th Annual Eastern States Conference, Hersey, Pennsylvania, May 2018.

Abstracts, continued

Regional

- 2016 Roy B, Owsiak R, **Casapao AM**. Statewide prevalence of Carbapenem-resistant Enterobacteriaceae from the first full year of required reporting through the Notifiable Conditions Rule. Maine Center for Disease Control and Prevention 2016 Division of Infectious Disease Annual Conference, Augusta, Maine, November 16, 2016; Abstract #11.
- 2016 **Casapao AM**, Grieser H, Meak S, Matluck N. Clinical Impact of Further Laboratory Diagnosis for Carbapenem Resistant Enterobacteriaceae. Maine Center for Disease Control and Prevention 2016 Division of Infectious Disease Annual Conference, Augusta, Maine, November 16, 2016; Abstract #5.
- 2015 Leichtweis CL, **Casapao AM**, Boudreau M, Mahlen S. Evaluation of empiric antimicrobial therapy and resistance of catheter-associated urinary tract infections versus non-catheter associated urinary tract infections in a level II trauma center. 35th Annual Eastern States Conference, Hersey, Pennsylvania, May 2015.
- 2014 **Casapao AM**, Lagnf AM, Rybak MJ. Temporal Characterization of Patients with Enterococcal Bloodstream Infection. 2014 Division of Infectious Disease Annual Conference, Augusta, Maine, November 19, 2014.
- 2015 Trafton M, Boudreau M, Seavey W, **Casapao AM**. A Quasi-Experimental Study to Evaluate Drug Administration Complication in the Use of Extended Infusion Piperacillin/Tazobactam. 34th Annual Eastern States Conference, Hersey, Pennsylvania, May 2015.
- 2014 Nagel JL, Pogue JM, Claeys KC, **Casapao AM**, Finks J, Davis SL, Rybak MJ. Utilization of the Center for Disease Control Antimicrobial Use and Resistance Module to Compare Multicenter Antimicrobial Prescribing on Medical, Surgical, and Intensive Care Units. 17th Annual Making a Difference in Infectious Diseases Pharmacotherapy Meeting, Orlando, FL, May 2014.
- 2014 Claeys KC, Nagel JL, Pogue JM, **Casapao AM**, Finks J, Davis SL, Rybak MJ. Implementing the National Healthcare Safety Network's Antibiotic Utilization and Resistance Program to Determine Resistance Among Key Nosocomial Pathogens. 17th Annual Making a Difference in Infectious Diseases Pharmacotherapy Meeting, Orlando, FL, May 2014.
- 2014 Bentley K, Epps K, Cannon C, **Casapao AM**, Tucker C. Evaluation of the Efficacy of Extended Infusion Piperacillin-Tazobactam Administration in Non-Intensive Care Unit Patients. 3rd Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, Gainesville, FL May 2014.
- 2014 Weissman A, Yiannos L, Ge, E, Mynatt RP, Rybak MJ, Millis S, **Casapao AM**, Levy P. A Retrospective Review of Empiric Antibiotic Selection in Patients Admitted with Urinary Tract Infection. 18th Annual New England Regional Society for Academic Emergency Medicine, New Haven, CT March 2014; Abstract #32A.

Abstracts, continued

Regional

- 2014 Weissman A, Yiannos L, Ge, E, Mynatt RP, Rybak MJ, Millis S, **Casapao AM**, Levy P. Appropriateness of Outpatient Empiric Antibiotic Selection in Patients with Urinary Tract Infections. 18th Annual New England Regional Society for Academic Emergency Medicine, New Haven, CT March 2014; Abstract #32.
- 2013 **Casapao AM**, Davis SL, Kullar R, Patel S, Levine DP, Rybak MJ. An Alternative Susceptibility Method as Predictor of Clinical Response to Vancomycin (VAN) with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 21st Annual Infectious Diseases Pharmacotherapy Fellowship Forum, York Harbor, ME, May 2013; Abstract #10. ***Presented as a research platform presentation.***
- 2012 **Casapao AM**, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). Star of the North 20th Annual Infectious Diseases Pharmacotherapy Fellowship Forum, Brainerd, MN, June 2012; Abstract #21. ***Presented as a research platform presentation.***
- 2012 **Casapao AM**, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Ceftaroline fosamil Therapy for *Staphylococcus aureus* Infections. 15th Making A Difference in Infectious Diseases Pharmacotherapy, Orlando, FL, March 2012; Abstract #5-OR FRS.
- 2011 **Casapao AM**, Kullar R, Leonard SN, Davis SL, Kaatz GW, Patel N, Lodise TP, Goff DA, Potoski BA, LaPlante KL, Rybak MJ. Clinical Outcomes in Patients with Vancomycin Heteroresistant *Staphylococcus aureus*. 8th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2011; Abstract #61.
- 2009 **Casapao AM**, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 44th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2009; Abstract #7-125. 41st Southeastern Residency Conference, Athens, GA, April 29-30 2009. ***Presented as a research platform presentation.***

Local

- 2022 Altamura E, Carrion Dominguez DA, **Casapao AM**, Egelund EF. Systematic Review of Medical Grade Honey versus Non-Medical Honey in Pet Wounds. 35th Annual Research Showcase University of Florida College of Pharmacy, February 2022.
- 2021 Lessing J, Boyle-Taylor J, Dupree L, **Casapao AM**. Competent versus developing abstract skills: does past writing experience matter? 34th Annual Research Showcase University of Florida College of Pharmacy, April 2021.
- 2021 Langley C, Chizmar A, Voils S, **Casapao AM**. Perception vs. reality: cross sectional study of the 2020 pharmacy residency match. 34th Annual Research Showcase University of Florida College of Pharmacy, April 2021.

Abstracts, continued

Local

- 2021 Venugopalan V, Hernandez S, DeSear K, Peloquin C, Cherabuddi K, **Casapao AM**. Use of therapeutic drug monitoring to optimise cephazolin dosing in the treatment of methicillin-susceptible *Staphylococcus aureus* bacteremia. 34th Annual Research Showcase University of Florida College of Pharmacy, April 2021.
- 2021 Carr A, Minor S, El Ghali, Kaur P, **Casapao AM**. Early real-world evidence in the use of eravacycline therapy for the management of draconian infections. 34th Annual Research Showcase University of Florida College of Pharmacy, April 2021.
- 2019 Bakare L, **Casapao AM**, Klinker KP, Childs-Kean LM, Pomputius AF, Allen JM. Cefazolin versus Anti-staphylococcal Penicillins for the Treatment of Patients with *Staphylococcus aureus* infection: A Meta-Analysis. 32nd Annual UF College of Pharmacy Research Showcase, Gainesville, Florida, February 2019.
- 2017 Kelley K, Nikornpan K, **Casapao AM**. Evaluation of Nephrotoxicity during Treatment with Vancomycin in Combination with Piperacillin-Tazobactam, Cefepime, or Meropenem. 8th Annual Husson Research and Scholarship Day, Bangor, Maine, April 20, 2017; Abstract #O-4.
- 2017 Ravin K, **Casapao AM**. Effect of hospital stay duration in patients treated with aztreonam vs cefepime for gram negative empiric therapy: interim analysis. Annual Husson Research and Scholarship Day, Bangor, Maine, April 20, 2017; Abstract #PP-2.
- 2016 Saab M, **Casapao AM**. Antibiotic Use in Acute Bacterial Skin and Skin Structure Infections. 7th Annual Husson Research and Scholarship Day, Bangor, Maine, April 21, 2016; Abstract #O-7.
- 2016 Rusby M, Thorton L, Ng YT, **Casapao AM**. Pharmacoepidemiology of pediatric patients with bronchiolitis. 7th Annual Husson Research and Scholarship Day, Bangor, Maine, April 21, 2016; Abstract #O-6.
- 2015 Pelletier J, **Casapao AM**. Analysis of Antimicrobial Therapy Optimization in Patients with *Escherichia coli* Bacteremia. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-6.
- 2015 Nya P, **Casapao AM**. Evaluation of *Staphylococcus aureus* Bacteremia in Adults with Renal Disease. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-5.
- 2015 Mehta, RM, **Casapao, AM**. The Impact of Erythromycin Resistance of Patients with *Staphylococcus aureus* Bacteremia. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-4.
- 2015 Egharevba E, **Casapao, AM**. Infectious Diseases Consultation May Improve Treatment Outcome Associated with *Staphylococcus aureus* Bacteremia. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-2.
- 2015 Akwuba V, **Casapao AM**. Clinical Outcomes of *Staphylococcus aureus* Bacteremia in Intravenous Drug Users. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-1.

Abstracts, continued

Local

- 2015 Duron A, **Casapao AM**. Eastern Maine Medical Center Quality Improvement Review of Optimizing Ceftriaxone Therapy. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #O-6.
- 2015 Rusby M, **Casapao AM**. Mortality Rates in Low-Risk, Intermediate-Risk, and High-Risk Patients. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #O-8.
- 2015 Wilson C, **Casapao AM**. An Epidemiological Study of Obese Patients with *Staphylococcus aureus* Bacteremia at Eastern Maine Medical Center. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #O-9.
- 2013 **Casapao AM**, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. Multicenter Experience of the Effectiveness and Safety with Ceftaroline Fosamil (CPT) Therapy. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #20.
- 2013 Claeys KC, **Casapao AM**, Goff DA, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin versus Vancomycin for Bloodstream Infection caused by Methicillin-Resistant *Staphylococcus aureus* (MRSA) Preliminary Results. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #68.
- 2013 Claeys KC, **Casapao AM**, Pogue JM, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Johnson LB, Davis SL, Rybak MJ. Characterization of Patients Treated for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Documented or at Risk of Methicillin-Resistant *Staphylococcus aureus* (MRSA). 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #67.
- 2013 Ni D, Rising K, **Casapao AM**, Barber KE, Mynatt RP, Rybak MJ. Vancomycin Consensus Guidelines Application and Serum Concentration Target Attainment. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #35.
- 2013 Divekar P, **Casapao AM**, Firestine SM, Rybak MJ, Martin ET. Comparative Study of Prevalence of pSK41 in Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA) Isolates Against non-hVISA Isolates. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #75.
- 2012 Barber KE, **Casapao AM**, Pogue JM, Kaye KS, Rybak MJ. Outcomes Associated with Vancomycin Intermediate *Staphylococcus aureus* (VISA) Bloodstream Infections (BSI). 9th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2012; Abstract #43.

Abstracts, continued

Local

- 2012 **Casapao AM**, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 9th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2012; Abstract #10.
- 2012 Martin ET, **Casapao AM**, McRoberts J, Archer C, Kaye KS, Rybak MJ. Low prevalence of Inc18-like *vanA* plasmid among prospectively-collected vancomycin-resistant *Enterococcus* isolates from Detroit Medical Center. 9th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2012.

Journal/Grant Peer Reviewer

BMC Infectious Diseases
Patient-Centered Outcomes Research Institute (PCORI)
Infectious Diseases and Therapy
Clinical Therapeutics
PLOS ONE
Pharmacotherapy
Annals of Pharmacotherapy (DICP)
Antimicrobial Agents Chemotherapy
Clinical Infectious Diseases
American Journal of the Medical Sciences
Infection Control and Hospital Epidemiology
F1000 Medicine Reports
Cureus

Platform Presentations and Continuing Education Presentations

National

- 2023 *Diagnostic Stewardship Process and Practice*
Presented CE and BCIDP credits to Pharmacists and Physicians. 25th Annual Making a Difference in Infectious Diseases (MAD-ID) Meeting, May, Orlando, Florida.
- 2023 *Meet the Professors*
Presented CE to Pharmacists and Physicians. 25th Annual Making a Difference in Infectious Diseases (MAD-ID) Meeting, May, Orlando, Florida.
- 2019 *Developing Diplomatic PharmaLeaders for the 21st Century: Leading to Leave a Legacy.*
Presented to Academic Faculty and Pharmacists. American Association of Colleges of Pharmacy (AACP) INVOLVE 2019 Interim Meeting, Tampa, Florida.

Regional

- 2022 *Antimicrobial Stewardship*
Presented CE for the certificate for Ambulatory Certificate for Pharmacists at the University of Florida College of Pharmacy
- 2022 *Community-acquired Pneumonia*
Presented CE for the certificate for Ambulatory Certificate for Pharmacists at the University of Florida College of Pharmacy

Platform Presentations and Continuing Education Presentations, continued

Regional

- 2022 *Skin and Soft Tissue Infections*
Presented CE for the certificate for Ambulatory Certificate for Pharmacists at the University of Florida College of Pharmacy
- 2021 *Streptococcal Infections: Testing, Treating and Managing*
Presented CE for the certificate for Test and Treat for Pharmacists at the University of Florida College of Pharmacy
- 2021 *Updates with Pneumonia Management: Inhale the New and Exhale the Old*
Presented CE to Pharmacists & Technicians at Florida Pharmacists Association
- 2021 *Pharmaceutical Verisimilitude: The Journey from Failure to Fortuity*
Presented to prospective students interested in joining University of Florida College of Pharmacy. Pharmacy Up Close and Virtual Series. Gainesville, Florida (*virtual*).
- 2018 *Antibiotic Stewardship Best Practices with Q&A*
Presented Webinar to Pharmacists, Nurses, and Healthcare providers with Health Care-Associated Infection Program and Florida Department of Health and Health
- 2017 *Achieving Optimal Health Outcomes through Outpatient Antimicrobial Stewardship*
Presented CE to Pharmacists & Technicians at regional Maine Society Health-System Pharmacists. UAN# 0837-9999-17-038-L01-P/T
- 2017 *Antimicrobial Stewardship: Advancing Patient Care by Improving Medication Use*
Presented CE to Pharmacists & Technicians at regional Maine Pharmacy Association UAN# 0837-9999-17-030-L01-P/T
- 2016 *The Rise of Antimicrobial Resistance and Antimicrobial Stewardship*
Presented CE to Pharmacists, Physicians, Nurses, Technicians at regional Maine CDC
- 2015 *Age of New Antimicrobials: Novelty versus Imitation*
Presented CE credit to Pharmacists, Pharmacy students and technicians at regional MSHP UAN#0837-9999-15-137-LO1-P/T

Local

- 2021 *Look into your heart.*
Presented to black female constituents of Duval County at River Region Human Services, Inc. Awareness of heart disease during American Heart Month/African American History Month. Heart of a Woman Program, Jacksonville, Florida.
- 2021 *Journey of a Wandering Star: Case of Becoming a Pharmacist.*
Presented to students at University of Florida. University of Florida Pre-Pharmacy Society, Gainesville, Florida.
- 2019 *Antibiotic Use Dogma: The Struggle between Preservation and Abuse.*
Presented to students and faculty at Jacksonville University. Science and Engineering Lectures Series at Jacksonville University, Jacksonville, Florida.

Platform Presentations and Continuing Education Presentations, cont.

Local

- 2019 *Research & Academia are the JAM! I'm so sure it's the future of pharmacy!*
Presented to Pharmacy Student Leaders and faculty at the University of Florida College of Pharmacy. Student Organization Annual Retreat (SOAR), Jacksonville, Florida.
- 2011 *Clinician's Guide to Optimizing Beta-Lactams through Extended Infusion*
Presented CE credit to Pharmacists and Pharmacy technicians, Pittsburgh, PA.
- 2011 *Drug Therapy Management of Clostridium difficile- Associated Diarrhea. Guideline Protocol and Order Set.*
Presented to Pharmacy and Therapeutics Committee. UPMC.
- 2011 *In vitro Susceptibilities of Fosfomycin against Enterobacteriaceae Producing KPC- Type Beta-Lactamases.*
Presented to ID grand rounds to ID physicians, fellows, medical residents clinical pharmacists, preceptors, and pharmacy students. UPMC, Pittsburgh, PA.
- 2011 *Novel Daptomycin Combination against Daptomycin-Nonsusceptible Methicillin Resistant Staphylococcus aureus. Journal Club.*
Presented to ID physicians, preceptors, fellows, and medical residents. UPMC.
- 2011 *Impact of Early Oseltamivir Treatment on Outcome in Critically ill Patients with 2009 Pandemic Influenza A. Journal Club.*
Presented to clinical pharmacists, preceptors, pharmacy residents and students. UPMC.
- 2011 *Principles of Antibiotics*
Monthly lecture presented to medical residents and students at UPMC.
- 2011 *Rapid Identification for Methicillin-Resistant Staphylococcus aureus Bacteremia. ID Grand Rounds Puzzler.*
Presented to ID physicians, fellows, medical residents and students. UPMC.
- 2010 *Therapeutic Drug Monitoring of Linezolid. Journal Club.*
Presented to clinical pharmacists, preceptors, pharmacy residents and students. UPMC.
- 2010 *Infective Endocarditis: Adjunctive Use of Ceftriaxone for the Treatment of Enterococcus Faecalis*
Presented to pharmacy residents, preceptors, students and faculty. UPMC.
- 2010 *Bugs & Drugs: The Rise of Gram-Negative Bacteria*
UAN: 0077-9999-10-014-L01-P; UPN: 0012-0000-10-074-H01-P
Presented CE credit to physicians, pharmacists, nurses, & medical technologists. SVMC.
- 2010 *Urinary Tract Infections in the Community Setting*
Presented to medical residents and attending physicians. SVMC.
- 2010 *Preventative Medicine and Health Maintenance*
Presented to pharmacy residents, preceptors, students and faculty. SVMC.
- 2010 *Carbapenem MUE and Drug Class Review*
Presented to pharmacy/therapeutics committee and medical executive committee. SVMC.

Platform Presentations and Continuing Education Presentations, cont.

Local

- 2010 *Human Papillomavirus Virus Update*
Presented to pharmacy residents, preceptors, students and faculty. SVMC.
- 2009 *Proper Use of Antibiotics In-Service*
Presented to family medicine residents and physicians. SVMC.
- 2009 *Clinical Trial Jeopardy*
Presented to pharmacy residents, preceptors, students and faculty. SVMC.
- 2009 *Cold and Cough Evidence Base Medicine Review*
Presented to pharmacy residents, preceptors, students and medical residents SVMC.
- 2009 *Drug Induced Nephrotoxicity*
Presented to pharmacy residents, preceptors, students and faculty. SVMC.
- 2009 *Beta-Lactam Dose Optimization in Critical Care Units In-Service*
Presented to pharmacists, physicians and nurses at St. Vincent's Medical Center.
- 2009 *Microsoft Excel and Data Collection*
Presented to pharmacy residents, preceptors, students and faculty. SVMC.
- 2009 *Prerenal Nephrotoxicity*
Presented to pharmacy residents, preceptors, students and faculty. SVMC.
- 2009 *Dronedarone In-Service*
Presented to nurses at St. Vincent's Medical Center
- 2009 *Update on H1N1 2009*
Presented to pharmacy residents, preceptors, students and faculty. SVMC.
- 2009 *Case Presentation: Septic Arthritis*
Presented to pharmacy residents, preceptors, students and faculty. SVMC.

Service and Leadership Activities

- | | |
|--------------------------|------------------------------------------------------------------------------------------------------------------------|
| July 2023 – Present | <i>Career Development</i>
University of Florida College of Pharmacy |
| August 2018 – Present | <i>Curriculum Committee</i>
University of Florida College of Pharmacy |
| 2014 – Present | <i>Student Mentor and Advisor</i>
University of Florida College of Pharmacy
Husson University School of Pharmacy |
| January 2021 – June 2023 | <i>Assessment Committee</i>
University of Florida College of Pharmacy |
| July 2020 – June 2022 | <i>Diversity, Equity and Inclusion Taskforce</i>
University of Florida College of Pharmacy |

Service and Leadership Activities, cont.

March 2017–December 2017	<i>Associate Editor</i> Harvard Public Health Review
February 2017–October 2017	<i>American Pharmacists Association Advisor</i> Husson University School of Pharmacy
July 2015–October 2017	<i>HAI Collaborating Partners Committee</i> Maine Center for Disease Control and Prevention
September 2014–October 2017	<i>Medication Management Committee</i> Eastern Maine Health System
September 2014–October 2017	<i>Antimicrobial Stewardship Committee</i> Eastern Maine Medical Center
September 2014–October 2017	<i>Infection Prevention and Control Function Team</i> Eastern Maine Medical Center
August 2014–May 2016	<i>Assessment Committee</i> Husson University School of Pharmacy
September 2014– August 2015	<i>Internet Committee</i> Society of Infectious Diseases Pharmacists (SIDP)
September 2012– August 2014	<i>Recognition Awards Committee</i> Society of Infectious Diseases Pharmacists (SIDP)
September 2011– August 2012	<i>Interorganizational Committee</i> Society of Infectious Diseases Pharmacists (SIDP)
2009 – 2010	<i>Organization Affairs Council</i> Florida Society of Health-System Pharmacists (FSHP) Establish a plan for membership development and retention including special membership benefits and promotions to target groups. Organize the FSHP Professional Policy and Procedure Manual.
2009 – 2014	<i>Electronic Mentor</i> Wingate University School of Pharmacy Respond to questions specific to practice, interests and passions while allowing first year pharmacy students to learn from the insight and real-world experiences of multiple mentors.
2007 – 2008	<i>Student Forum Membership Advisory Group</i> National Student Forum of ASHP Promoted student membership by highlighting the value of ASHP. Evaluated current student member benefits and services. Promoted careers in health-system pharmacy and disseminated health system information
2007 – 2008	<i>ASHP-Student Society President</i> Wingate University School of Pharmacy

Service and Leadership Activities, cont.

2007 – 2008	<i>Professionalization Committee Student Representative</i> Wingate University School of Pharmacy Deliberated on student honors and awards and developed an annual special activity calendar of professional opportunities.
2005 – 2007	<i>ASHP-Student Society Liaison</i> Wingate University School of Pharmacy Promoted involvement in professional service activities to enhance student professionalism and support the university and community.
2003 – 2004	<i>Class Treasurer</i> Midwestern University College of Health Science Initiated fundraisers to assist professionalism and budgeted Midwestern University Biomedical Science Program funds.

Professional Associations

2012 – Present	European Society of Clinical Microbiology and Infectious Diseases
2011 – Present	Society of Infectious Diseases of Pharmacists (SIDP)
2011 – Present	Infectious Diseases Society of America (IDSA)
2005 – 2019	American College of Clinical Pharmacy (ACCP)
2014 – 2019	American Association of Colleges of Pharmacy (AAPC)
2009 – 2018	Florida Society of Health-System Pharmacist (FSHP)
2011 – 2016	American Society for Microbiology (ASM)
2010 – 2011	Pennsylvania Society of Health-System Pharmacist (PSHP)
2005 – 2010	American Society of Health-System Pharmacist (ASHP)
2005 – 2009	North Carolina Association of Pharmacists (NCAP)
2005 – 2008	American Pharmacists Association (APhA)

Funded Research Grants

2019	Casapao AM. Co-Investigator. Predictors of sub-therapeutic beta-lactam serum concentrations in the acute phase of septic shock. University of Florida Health Sciences Center Dean's Fund Research Award. (\$10,000 12/01/2019-12/31/2020).
2018	Casapao AM. Co-Investigator. Accuracy and Reliability of Finger Stick Capillary Blood Sampling for Therapeutic Drug Monitoring of Vancomycin Levels and Basic Metabolic Profile. University of Florida Health Science Center Dean's Fund Research Award. (\$5,000 04/01/2018-12/31/2019).
2018	Casapao AM. Principal Investigator. Impact of Antimicrobial Use for the Management of for the Management of Hospital acquired Pneumonia and Ventilator associated Pneumonia: A Time Series Analysis of the Infectious Diseases Society of America and American Thoracic Society Publication of Clinical Practice Guidelines. 2017 IDSA Education and Research Foundation Young Investigator Award in Infectious Diseases. Proposal submitted and Funding denied.
2018	Casapao AM. Principal Investigator. Impact of Delaying Antibiotic Prescriptions for Patients with Chronic Obstructive Pulmonary Disease: Antimicrobial Stewardship Initiative. NACDS Foundation. Proposal submitted and Funding denied.

Funded Research Grants, cont.

- 2017 Casapao AM. Co-Investigator. Development and Implementation of Intramural Comprehensive Examination for P2s. Intramural Husson University School of Pharmacy. (\$3,825 01/01/2017-12/31/2017).
- 2016 Casapao AM. Co-Investigator. Pharmacoeconomics of Antimicrobial Therapy Optimization in Patients with Escherichia coli Bloodstream Infection. Intramural Husson University School of Pharmacy. (\$3,500 07/01/2016-06/30/2016).
- 2016 Casapao AM. Co-Investigator. Oritavancin Assay Development continuation. Intramural Husson University School of Pharmacy. (\$3,000 07/01/2016-06/30/2016).
- 2016 Casapao AM. Co-Investigator. Oritavancin Assay Development Pilot Study. Intramural Husson University School of Pharmacy. (\$4,000 07/01/2015-06/30/2016).
- 2015 Casapao AM. Co-Investigator. Characterization of the Treatment of Candiduria. Astellas Pharma US, Inc. (\$62,614 01/01/2015-12/31/2015).
- 2015 Casapao AM. Principal Investigator. Ten Year Epidemiology Report of *Staphylococcus aureus* Infections in State of Maine. American Association of Colleges of Pharmacy. Protocol submitted and Funding denied.
- 2014 Casapao AM. Principal Investigator. Impact of Early Beta-Lactam Therapy in Combination with Standard Therapy for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. Intramural Husson University School of Pharmacy. (\$8,000 07/01/2014-06/30/2016).
- 2014 Casapao AM. Co-Investigator. Patient Outcomes Burden of Illness with Lower Respiratory Infections in Intensive Care Units. Cubist Pharmaceuticals Inc. (\$151,996 08/01/2014-07/31/2016).
- 2013 Casapao AM. Co-Investigator. Cost-Analysis of Rapid Identification with Nanosphere Verigene Blood Culture Assay in Patients with Suspected Gram-Positive Bacteremia. Nanosphere. Protocol submitted and Funding denied.
- 2013 Casapao AM. Co-Investigator. Impact of Early Daptomycin versus Vancomycin Therapy for Bloodstream Infection Caused by Methicillin-Resistant *Staphylococcus aureus*. Cubist Pharmaceuticals Inc. (\$177,792.50 02/01/2013-02/01/2015)
- 2013 Casapao AM. Co-Investigator. A Retrospective, Comparative Evaluation of Acute Bacterial Skin and Skin Structure Infections Receiving Ceftaroline or Vancomycin. Forest Research Institute. Protocol submitted and Funding denied.
- 2012 Casapao AM. Co-Investigator. Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections with Documented or at Risk of Methicillin-Resistant *Staphylococcus aureus*. Forest Research Institute. (\$254,310.00 04/01/2012-04/30/2014)
- 2011 Casapao AM. Co-Investigator. Antimicrobial Use and Resistance (AUR) Option. National Healthcare Safety Network (NHSN) and Michigan Department of Community Health (MDCH). (\$223,491.24 08/01/2011-07/31/2013)
- 2011 Casapao AM. Co-Investigator. High-Dose Daptomycin for Enterococcal Infections; A multi-center evaluation. Cubist Pharmaceuticals. (\$134,750.00 6/01/10-10/31/12)

Honors and Awards

2017	Williams F. Beardsley Teaching Excellence Award – Husson University
2017	P4 Teacher of the Year – Husson University School of Pharmacy
2016	Distinguished Research Award – Husson University
2014-2017	Intramural Husson University School of Pharmacy Research Grant
2014	24 th ECCMID Travel Grant
2013	16 th MAD-ID Travel Grant
2013	23 rd ECCMID Travel Grant
2012	52 nd ICAAC Post-Doctoral Travel Grant
2012	15 th MAD-ID Travel Grant
2011	51 st ICAAC ID Fellows Grant
2009	Cum Laude, Wingate University School of Pharmacy
2007	Inducted into Phi Lambda Sigma
2005	Magna Cum Laude, Midwestern University

Licensures and Certifications

2018 – Present	Board Certified Infectious Diseases Pharmacist – BCIDP
2009 – Present	Registered Pharmacist, State of Florida Board of Pharmacy